Valuation of Vaxcyte, Inc. (PCVX): P/B 3.93, EV/EBITDA -7.2, dividend yield 0.00%. The price range it would trade at on its usual multiples and on its sector's, with its peers' multiples and a comparison against other Healthcare companies.
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At $65.68 (closing price, November 4, 2026), PCVX has negative trailing earnings (P/E not meaningful) and an ROE of -42.04%. Market capitalisation stands at $10.3B, placing it among large-cap names.
Balance sheet quality for PCVX: debt-to-equity ratio of 0.09, current ratio of 7.66 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 3.93 |
| EV / EBITDA | -7.2 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PCVX | Vaxcyte, Inc. | $10.3B | 3.93 | -42.0% | |
| MRNA | Moderna, Inc. | $103.2B | 15.13 | -39.2% | |
| IBRX | ImmunityBio, Inc. | $9.5B | 135.0% | ||
| PFE | Pfizer Inc. | $175.5B | 44.19 | 1.97 | 4.6% |
| GSK | GSK plc | $103.7B | 17.92 | 4.14 | 24.6% |
Price
| Price | $65.68 (closing price, November 4, 2026) |
| Market Cap | $10.3B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -42.04% |
| Return on Invested Capital | -33.96% |
| Return on Assets | -38.42% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: MRNA · IBRX · PFE · GSK
Explore sector: Healthcare · Biotechnology
More sections of PCVX: Overview · Financials · Estimates · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks